Dicker Valentina, Serna Posada Maria Del Mar, Galeano Piedrahita Estefania, Vasquez Villegas Sara, Perez Madrid Camila
Aesthetic Medicine, Dra Skin, Medellín, COL.
Dermatology, Dra Skin, Medellín, COL.
Cureus. 2025 Feb 13;17(2):e78957. doi: 10.7759/cureus.78957. eCollection 2025 Feb.
Most previous studies of botulinum toxin A (BoNT/A) use for rosacea have reported using hyperdiluted BoNT/A. Different dilutions than the standard practiced dilution for wrinkle treatment result in confusion, especially if there is more than one injector in an office because daily logistics become complicated.
To evaluate the safety and efficacy of the use of intradermal injections of incobotulinumtoxin A (INCO) in the standard dilution used for wrinkle treatment (100U vial in 2cc) for the treatment of erythematotelangiectatic rosacea (ETR).
Data from 13 patients with ETR treated with INCO were prospectively collected in this single-center, open-label preliminary study. Patients answered the Rosacea-specific Quality-of-Life instrument (RosaQol) questionnaire, and a non-treating blinded dermatologist evaluated the Clinician Erythema Assessment (CEA) score using a five-point grading scale at baseline and 15-day and three-month follow-ups.
A significant decrease occurred in the total RosaQoL score at 15-day and three-month (p<0.001) follow-ups compared to baseline. Baseline CEA score was considered moderate (84.6%) or severe (15.4%). Most patients were assessed as almost clear or mild at the 15-day and three-month follow-ups (99.3% and 88.9%, respectively).
Standard 2mL dilution INCO, used for aesthetic indications, may be a safe and effective option for treating ETR-related erythema and flushing.
以往大多数关于肉毒杆菌毒素A（BoNT/A）用于治疗玫瑰痤疮的研究都报告使用了超稀释的BoNT/A。与用于皱纹治疗的标准实际稀释度不同的稀释度会导致混淆，尤其是在一个科室中有多名注射医生时，因为日常操作会变得复杂。
评估用于皱纹治疗的标准稀释度（2毫升中含100单位小瓶）的皮内注射英恪令（INCO）治疗红斑毛细血管扩张型玫瑰痤疮（ETR）的安全性和有效性。
在这项单中心、开放标签的初步研究中，前瞻性收集了13例接受INCO治疗的ETR患者的数据。患者回答玫瑰痤疮特异性生活质量量表（RosaQol）问卷，一位不参与治疗的皮肤科医生在基线、15天和三个月随访时使用五点分级量表评估临床医生红斑评估（CEA）评分。
与基线相比，在15天和三个月随访时，RosaQoL总分显著降低（p<0.001）。基线CEA评分被认为是中度（84.6%）或重度（15.4%）。在15天和三个月随访时，大多数患者被评估为几乎消退或轻度（分别为99.3%和88.9%）。
用于美容适应症的标准2毫升稀释度INCO可能是治疗ETR相关红斑和潮红的安全有效选择。
